https://www.selleckchem.com/products/arq-197.html
25 and -1.09); daily bowel movement frequency (-1.48 and -0.79); daily urgent bowel movements (-0.52 and -0.8; IBS-QoL (5.9 and 13.6); serum 7αC4 (-5.59 and -8.78ng/mL). There were no deaths, serious treatment-emergent adverse events, or discontinuations due to adverse events during the study. Eluxadoline is similarly efficacious in the treatment of IBS-D and BAD, and it appears to be safe and efficacious as documented in large clinical trials. Eluxadoline is similarly efficacious in the treatment of IBS-D and BAD, and it appears to b
Curtir
Comentario
Compartilhar
